Freenome Holdings Inc., a South San Francisco, Calif.-based startup developing a blood test to screen for colorectal cancer, landed a $290 million investment from Roche, bringing the total raised by the company to more than $1.1 billion. Last month, Freenome said it raised a $300 million Series D round from investors including Perceptive Advisors, RA Capital Management, Andreessen Horowitz, Bain Capital Life Sciences and GV.
Transcarent, a Palo Alto, Calif.-based provider of healthcare services for employees of self-insured employers, raised $200 million in Series C funding. Kinnevik and Human Capital led the round, which included additional support from General Catalyst, 7wireVentures, Alta Partners, Merck Global Health Innovation Fund, Jove Equity Partners, Threshold Ventures, GreatPoint Ventures, Ally Bridge Group, Northwell Health, Intermountain Healthcare and Rush University Medical Center.
Maze Therapeutics Inc., a South San Francisco, Calif.-based startup translating genetic insights into new precision medicines, scored a $190 million investment. Matrix Capital Management led the round, which included participation from General Catalyst, Andreessen Horowitz, Woodline Partners, Casdin Capital, City Hill Ventures, Foresite Capital, Driehaus Capital Management, Moore Strategic Ventures, Terra Magnum Capital Partners, NS Investments and others. Matrix Capital Management’s Andy Tran joined Maze’s board.
Shanghai ZhenGe Biotech Co., a Shanghai-based drug development startup, completed a $100 million Series C round. Goldman Sachs Asset Management and Sofina led the investment, which included contributions from Novo Holdings, Qiming Venture Capital, IDG Capital, LYFE Capital, Junxin Capital and Cowin Capital.
DexCare Inc., a Seattle-based digital care operating system provider, gathered a $50 million Series B round. Led by Transformation Capital, the investment included support from Kaiser Permanente, Providence Ventures, Mass General Brigham, Define Ventures, Frist Cressey Ventures and SpringRock Ventures.
Chapter, a New York-based Medicare advisor startup, secured $42 million in Series B funding. Addition led the round, which saw participation from Narya Capital, Susa Ventures, Maverick Ventures, XYZ Venture Capital and Health2047 Capital Partners.
DeepScribe, a San Francisco-based medical scribe technology startup, picked up a $30 million investment. Nina Achadjian of Index Ventures led the round, which included participation from Bee Partners, Stage 2 Capital, 1984 Ventures and others.
PostEra, a Boston-based company specializing in machine learning for preclinical drug discovery, raised $24 million in Series A funding. Lead investor Clermont Group was joined by Breyer Capital, Lifeforce Capital, I2BF Global Ventures, Metaplanet, HOF Capital, Ace & Company and Pioneer Fund.
Chronus Health Inc., a Mountain View, Calif.-based developer of portable blood analyzer technology, snagged $22 million in Series A financing. Tarsadia Investments led the round, which included contributions from Monta Vista Capital, SOSV and Savantus Ventures.
Scitara Corp., a Marlborough, Mass.-based digital lab startup, added $15 million in Series B funding. Northpond Ventures led the round, with additional participation from Flybridge Capital and others.
Diana Health, a New York-based women’s health provider, launched with $11 million in Series A financing. Lead investors LRVHealth and .406 Ventures were joined by AlleyCorp in the round. Payal Divakaran of .406 Ventures and Ellen Herlacher of LRVHealth will join the company’s board.
PreciseDx, a New York provider of cancer risk stratification services, fetched $10.8 million in Series A funding. Merck Global Health Innovation Fund led the round, which saw participation from IBM Ventures, Mount Sinai Health System and others.
HeyRenee, a Los Angeles-based personal healthcare assistant, raised a $4.4 million Seed II round led by Quiet Capital, with participation from City Light Capital, Fika Ventures, Global Founders Capital, Mucker Capital, SaaS Ventures and Tau Ventures.
|